We invest in life

Ridgeline, a Versant Ventures Discovery Engine located in Switzerland, creates new biotech companies in partnership with entrepreneurs, industry and leading academics across Europe.

About us

Ridgeline, a Versant Ventures Discovery Engine, was founded in early 2017 to create and operate Versant-financed innovative biotech companies in Basel, Switzerland. In its first year Ridgeline assembled an international team of 20 highly experienced drug discovery professionals and built and operated three new companies, including Black Diamond, Bright Peak and Monte Rosa.

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 75 Versant companies have achieved successful acquisitions or IPOs. Versant is currently investing out of its seventh fund, Versant Venture Capital VII, a $600 million global biotech fund closed in December 2018. In parallel the firm co-invests out of its Canadian strategic fund Versant Voyageurs I and its later-stage biotech opportunity fund Versant Vantage I. For more information, please visit www.versantventures.com.

Accessing the best science and innovation

Ridgeline – A Versant Ventures Discovery Engine


 Ridgeline is rapidly developing the foundational science and technology of our new companies. Our goal is to grow these newcos into leading biotechs.


We partner with entrepreneurs and leading academics across Europe to access breakthrough transformational science that serves as the foundation of our company creation efforts.


Together with our academic founders, our international team of accomplished industry R&D veterans drives research to create novel platforms and high-quality therapeutic candidates.


Our international team has deep investment, research and operating experience that enables an efficient, hands-on approach to company building and value creation.

Discovery Engines

Novel platforms, breakthrough therapies


Giorgio Ottaviani, PhD., DABT

is VP of Preclinical Development at Ridgeline.

Fang Z. Ni, Pharm.D.

is a Principal at Versant Ventures and acting CBO at Ridgeline.

Board of Directors

Getting in touch


Ridgeline Therapeutics GmbH
A Versant Ventures Discovery Engine

Aeschenvorstadt 36

CH 4051 Basel



Offices  and Labs

Ridgeline Therapeutics GmbH
Hochbergerstrasse 60C
CH 4057 Basel


A Versant Ventures Discovery Engine.




Imprint  /  Privacy Policy  /  Terms of Use

© 2018 Ridgeline Therapeutics GmbH

We invest in life


the best science and innovation

platforms, breakthrough therapies